Evidence map›Paper›PMID 27257917›Full record

ArticlePloS one2016

Quantification and Comparison of Anti-Fibrotic Therapies by Polarized SRM and SHG-Based Morphometry in Rat UUO Model.

Hu Sheng Qian, Steve M Weldon, Damian Matera, ChungWein Lee, Haichun Yang, Ryan M Fryer, Agnes B Fogo, Glenn A Reinhart

Open access · goldAbstract readComparative Study
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Banff Digital Pathology Working Group: Going digital in transplant pathology.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2020
    Article
  5. Cyclin G1 and TASCC regulate kidney epithelial cell GScience translational medicine · 2019
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Hu Sheng QianCardioMetabolic Disease Research, Boehringer Ingelheim Pharmaceutics, Inc, Ridgefield, Connecticut, United States of America.ORCID http://orcid.org/0000-0001-5296-1573
Steve M WeldonCardioMetabolic Disease Research, Boehringer Ingelheim Pharmaceutics, Inc, Ridgefield, Connecticut, United States of America.
Damian MateraCardioMetabolic Disease Research, Boehringer Ingelheim Pharmaceutics, Inc, Ridgefield, Connecticut, United States of America.
ChungWein LeeCardioMetabolic Disease Research, Boehringer Ingelheim Pharmaceutics, Inc, Ridgefield, Connecticut, United States of America.
Haichun YangDepartment of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America.
Ryan M FryerCardioMetabolic Disease Research, Boehringer Ingelheim Pharmaceutics, Inc, Ridgefield, Connecticut, United States of America.
Agnes B FogoDepartment of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America.
Glenn A ReinhartCardioMetabolic Disease Research, Boehringer Ingelheim Pharmaceutics, Inc, Ridgefield, Connecticut, United States of America.
Boehringer Ingelheim (United States) · USVanderbilt University · US

Funding

RESOLUTION OF GLOMERULOSCLEROSISR01DK056942 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI FOGO, AGNES B. · 2001 to 2021
$4.9M
NIDDK NIH HHS R01 DK056942
6 · The paper itself

Abstract

Renal interstitial fibrosis (IF) is an important pathologic manifestation of disease progression in a variety of chronic kidney diseases (CKD). However, the quantitative and reproducible analysis of IF remains a challenge, especially in experimental animal models of progressive IF. In this study, we compare traditional polarized Sirius Red morphometry (SRM) to novel Second Harmonic Generation (SHG)-based morphometry of unstained tissues for quantitative analysis of IF in the rat 5 day unilateral ureteral obstruction (UUO) model. To validate the specificity of SHG for detecting fibrillar collagen components in IF, co-localization studies for collagens type I, III, and IV were performed using IHC. In addition, we examined the correlation, dynamic range, sensitivity, and ability of polarized SRM and SHG-based morphometry to detect an anti-fibrotic effect of three different treatment regimens. Comparisons were made across three separate studies in which animals were treated with three mechanistically distinct pharmacologic agents: enalapril (ENA, 15, 30, 60 mg/kg), mycophenolate mofetil (MMF, 2, 20 mg/kg) or the connective tissue growth factor (CTGF) neutralizing antibody, EX75606 (1, 3, 10 mg/kg). Our results demonstrate a strong co-localization of the SHG signal with fibrillar collagens I and III but not non-fibrillar collagen IV. Quantitative IF, calculated as percent cortical area of fibrosis, demonstrated similar response profile for both polarized SRM and SHG-based morphometry. The two methodologies exhibited a strong correlation across all three pharmacology studies (r2 = 0.89-0.96). However, compared with polarized SRM, SHG-based morphometry delivered a greater dynamic range and absolute magnitude of reduction of IF after treatment. In summary, we demonstrate that SHG-based morphometry in unstained kidney tissues is comparable to polarized SRM for quantitation of fibrillar collagens, but with an enhanced sensitivity to detect treatment-induced reductions in IF. Thus, performing SHG-based morphometry on unstained kidney tissue is a reliable alternative to traditional polarized SRM for quantitative analysis of IF.

Indexed as

AnimalsAntibodies, MonoclonalAzo CompoundsCollagenDose-Response Relationship, DrugEnalaprilFibrosisKidney DiseasesMaleMycophenolic AcidNon-Fibrillar CollagensRatsRats, Sprague-DawleyReproducibility of ResultsUreteral ObstructionAntibodies, MonoclonalAzo CompoundsCollagenDirect Red 81EnalaprilMycophenolic AcidNon-Fibrillar Collagens

Identifiers

PMID27257917
PMCPMC4892485
OpenAlexW2413924722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.